Panagora Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Panagora Asset Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-29,676	Closed	-$121K	–	1525
2023 Q1	$121K	Sell	29,676 -126,246	-81%	-$583K	﹤0.01%	1411
2022 Q4	$783K	Buy	155,922 +11,778	+8%	+$73.8K	0.01%	984
2022 Q3	$1.89M	Buy	144,144 +48,639	+51%	+$737K	0.01%	613
2022 Q2	$1.22M	Buy	95,505 +22,689	+31%	+$314K	0.01%	809
2022 Q1	$1.11M	Buy	72,816 +5,750	+9%	+$89.7K	0.01%	885
2021 Q4	$1.19M	Buy	+67,066	New	+$1.29M	0.01%	839

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Panagora Asset Management's NGM Position: Q2 2023 in Review

Panagora Asset Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 29,676 shares — an estimated $121K sold.

Panagora Asset Management first reported a position in NGM in Q4 2021 and held it in 6 quarters. The position peaked at $1.89M in Q3 2022. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

Panagora Asset Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Panagora Asset Management sold 29,676 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $121K.
Panagora Asset Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Panagora Asset Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.89M in Q3 2022.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Panagora Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.